NCT07182591View on ClinicalTrials.gov

A Study of DS5361b in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

October 2, 2025

Primary Completion Date

March 18, 2030

Study Completion Date

December 3, 2030

Conditions
Advanced Solid Tumor
Interventions
DRUG

DS5361b

"Dose Escalation Part: DS5361b will be administered at escalating doses to determine the RDE.~Dose Expansion Part: DS5361b will be administered at RDE."

DRUG

Pembrolizumab

"Dose Escalation Part: Pembrolizumab will be administered at a standard dose.~Dose Expansion Part: Pembrolizumab will be administered at a standard dose."

Trial Locations (2)

75039

RECRUITING

Research Site, Irving

78229

RECRUITING

Research Site, San Antonio

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY